

June 17<sup>th</sup>, 2021

Company Name	UBIENCE Inc.	
Representative	President	Yasuhiro IWATA
Inquiries	Contact person	Hirobumi TAKEUCHI
	(e-mail: <a href="mailto:recep_info@ubience.com">recep_info@ubience.com</a> )	

**Notice of Transition to a Company with a Board of Directors and a Company with Corporate Auditors,  
Election of Directors, Election of Corporate Auditors and Change of Representative Director**

At the Extraordinary General Meeting of Shareholders of UBIENCE Inc. (the "Company") held today, the Company transition to a Company with a Board of Directors and a Company with Corporate Auditors, Election of Directors, Election of Corporate Auditors and Change of Representative Director, as follows.

1. Reason of Transition to the Board of Directors  
By establishing the Board of Directors, we will speed up the decision-making process for business execution and strengthen the legality of business execution and corporate governance.
2. Reason of Transition to the Corporate Auditors  
In addition to strengthening the supervisory function of the Board of Directors, we will further enhance corporate governance by strengthening the auditing and supervisory functions for the legality and appropriateness of business execution.
3. Newly Appointed Directors  
Yasuhiro IWATA  
Nobuyuki TAKAHASHI
4. Newly Appointed Corporate Auditor  
Atsuko SUYAMA
5. Change of Representative Director
  - (1) Details of Change

Incoming Representative Director	Yasuhiro IWATA
Outgoing Representative Director	Hirobumi TAKEUCHI
  - (2) Reason of Change  
After completing the 1st close of the seed round, Company appointed Mr. Iwata, who has extensive experience in Medicinal Chemistry, to accelerate our R&D. Mr. Takeuchi will continue to contribute to the Company as a director and co-founder.
6. Effective Date of Changes  
June 17<sup>th</sup>, 2021

####